Integrating High-Dose GLP-1 Receptor Agonists Into the Care of People With or at Risk for Type 2 Diabetes

Abstract

Get full access to this article

View all access options for this article.

References

ADA. Standards of medical care in diabetes-2022. Diabetes Care. 2022;45:S1-S264.

Apovian

Aronne

Bessesen

, et al. Pharmacological management of obesity: an Endocrine Society Clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362. doi:10.1210/jc.2014-3415

Cameron

Petito

McCabe

, et al. Quantifying the sex-race/ethnicity-specific burden of obesity on incident diabetes mellitus in the United States, 2001 to 2016: MESA and NHANES. J Am Heart Assoc. 2021;10(4):e018799. doi:10.1161/JAHA.120.018799

Centers for Disease Control and Prevention. Diabetes and prediabetes. Secondary diabetes and prediabetes 2020. https://www.cdc.gov/chronicdisease/resources/publications/factsheets/diabetes-prediabetes.htm

Centers for Disease Control and Prevention. Diabetes report card 2019. Secondary diabetes report card 2019 2021. https://www.cdc.gov/diabetes/library/reports/reportcard.html

Davies

Bergenstal

Bode

, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687-699.

Davies

Faerch

Jeppesen

, et al. Semaglutide 2-4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984.

The Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25(12):2165-2171.

Frfas

Auerbach

Bajaj

, et al. Efficacy and safety of once-weekly semaglutide 2-0 mg versus 1-0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563-574. doi:10.1016/S2213-8587(21)00174-1

10.

Frias

Bonora

Nevarez Ruiz

, et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021;44(3):765-773.

11.

Garvey

Mechanick

Brett

, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. EndocrPract. 2016;22:1-203. doi:10.4158/EP161365.GL

12.

Pi-Sunyer

Astrup

Fujioka

, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22.

13.

Rubino

Abrahamsson

Davies

, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425.

14.

Wadden

Bailey

Billings

, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413.

15.

Wadden

Hollander

Klein

, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2013;37(11):1443-1451.

16.

Wilding

JPH

Batterham

CalannaS

, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.